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1002Paclitaxel Drug-Coated Balloons
A Review of Current Status and Emerging Applications
in Native Coronary Artery De Novo Lesions
The paclitaxel drug-coated balloon (DCB) is an emerging device in percutaneous coronary intervention, which has
shown promising results by means of a high-concentration, rapid local release of an antirestenotic drug without the
use of a durable polymer or metal scaffold. DCB have already proven effective in clinical trials for the treatment of
in-stent restenosis. Its coronary applications may potentially be widened to a host of complex coronary de novo le-
sion subsets, such as small-caliber vessels, diabetes, and diffuse lesions, where the use of stents may be hampered
by suboptimal results. Recently, this technology has rapidly evolved with newer studies added to assess the value of
DCB in coronary applications other than in-stent restenosis. We present a review of the role of DCB in de novo cor-
onary lesions based on this latest clinical evidence. (J Am Coll Cardiol Intv 2012;5:1001–12) © 2012 by the
American College of Cardiology FoundationThe paclitaxel drug-coated balloon (DCB) is an emerg-
ing device in percutaneous coronary intervention (PCI)
developed to circumvent some of the limitations faced by
drug-eluting stents (DES). These limitations include late
and very late stent thrombosis (ST) (1); bleeding risks
associated with prolonged dual antiplatelet therapy
(DAPT) (2); and reduced efficacy in complex patient and
lesion subsets (3). DCB are semicompliant angioplasty
balloons covered with an antirestenotic drug that is
rapidly released locally into the vessel wall during balloon
contact. Various companies manufacture paclitaxel-
coated DCB because of their lipophilicity and tissue
retention characteristics (4). Table 1 shows the DCB
urrently being evaluated in coronary applications. These
aclitaxel DCB differ in drug-delivery technology and
xcipients used, thereby resulting in differences in specific
lution kinetics and tissue retention (5). These mecha-
istic differences are not well understood, however, and
heir clinical significance is even less clear.
DCB technology has demonstrated safety and efficacy in the
reatment of coronary in-stent restenosis (6–8). Currently,
are-metal stent (BMS) in-stent restenosis is the only ap-
roved indication for DCB use in the European guidelines.
he purpose of this review is to detail the other emerging
ndications for the utilization of DCB for de novo coronary
esions, to present the available clinical data, and to discuss
heir potential role in this area.
CB Use in Small Vessel Disease
Stents have limited utility in small-caliber coronary arteries,
hampered by late lumen loss (LLL), which is found to be
independent of vessel diameter (9,10). Even with DES use,
small vessel size remains a strong predictor of restenosis
(11). The potential advantage of DCB is less vessel inflam-mation in the absence of metallic stents and polymer, while
allowing the artery’s original anatomy to remain intact, thus
reducing abnormal flow patterns (5).
The first study to explore DCB use in small vessels was
the PEPCAD (Paclitaxel Eluting PTCA Balloon in Cor-
onary Artery Disease) I study, a single-arm trial investigat-
ing SeQuent Please DCB (B. Braun Melsungen AG,
Berlin, Germany) in vessels with a mean diameter of 2.36
mm (12) (Table 2). The DCB-only group achieved impres-
sive angiographic and clinical results at 6 months (binary
restenosis: 5.5%; target lesion revascularization [TLR]:
4.9%). In contrast, 28% of patients who had BMS fared
much worse, with 8 higher restenosis and 5 higher
TLR. Most restenosis (77%) occurred at the stent edges,
highlighting the potential pitfall of geographic mismatch
where a longer BMS was placed outside of the shorter
DCB-treated area. Vessel thrombosis occurred in 6.3% of
the DCB  BMS group and in no patient from the
DCB-only group, despite a longer duration of DAPT (3
months vs. 1 month).
The PICCOLETTO (Paclitaxel-Coated Balloon Versus
Drug-Eluting Stent During Percutaneous Coronary Inter-
vention of Small Coronary Vessels) study was the first
randomized trial comparing first-generation Dior-I DCB
(Eurocor, Bonn, Germany) with Taxus Libertè DES (Bos-
ton Scientific Corporation, Natick, Massachusetts) in ves-
sels 2.75 mm in diameter (13). This study was halted
prematurely due to clear superiority of the DES group
demonstrating less restenosis and a trend toward lower
TLR. The worse-than-expected results, as compared to
PEPCAD I, were attributed to lower tissue drug dosage in
the Dior-I DCB. In addition, procedural differences, such
as lower pre-dilation rates and lower inflation pressures
employed in the DCB group, may have adversely affected its
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1003outcome. Contrary to PEPCAD I, binary restenosis was
similar between DCB with bailout BMS and DCB-only
subgroups, suggesting the possibility of exploring routine
BMS implantation after DCB in future studies.
The prospective Spanish DIOR (Results of Paclitaxel Elut-
ing Balloon) registry assessed first- and second-generation
Dior DCB in very small vessels (mean diameter: 1.99 mm) and
demonstrated encouraging preliminary results (14). Angio-
graphic restenosis occurred in 20% of cases, but only 3%
required revascularization; the 1-year major adverse cardiac
event (MACE) rate was low at 5.8%. In contrast to the other
studies, only 7% required bailout BMS to treat dissections.
Positive findings were presented from the BELLO (Bal-
loon Elution and Late Loss Optimization) trial, a random-
ized study comparing the In.Pact Falcon DCB (Medtronic-
Invatec, Fraunfeld, Switzerland) to Taxus DES in vessels
with a mean diameter of 2.15 mm (15). The DCB demon-
strated superiority over the DES in the primary endpoint of
LLL at 6 months (0.09 vs. 0.30 mm, p  0.001). However,
bailout BMS occurred in 21.1% of DCB patients; in this
group, LLL was 0.33 mm, approximating the DES result.
MACE rates at follow-up were comparable between DCB
and DES groups (10% vs. 16.3%, p  0.18).
From these limited data, it appears that a DCB-only
strategy with provisional BMS might be a reasonable and
attractive approach in small vessels, avoiding further reduc-
tion of lumen diameter with stent struts. The upcoming
DCB-only small vessel disease worldwide registry set up by
the PEPCAD investigators will add further insight into the
utility of the DCB-only strategy in small vessels.
DCB  BMS in De Novo Coronary Lesions
DES use is limited by accrued risks of late ST facilitated by
delayed stent endothelial coverage; dependence on pro-
longed DAPT also accounts for higher costs and increased
bleeding risks. Whereas DCB provide homogeneous and
rapid antiproliferative drug transfer to the entire vessel,
inhibiting neointimal hyperplasia with little impact on
long-term healing, they cannot overcome the mechanical
limitation of acute recoil post-balloon angioplasty. By com-
bining DCB and BMS, this has the potential for improved
long-term safety while requiring a shorter DAPT duration
and may be a viable therapeutic alternative to DES use in
at-risk patients.
The LOCAL TAX (Local Intracoronary Delivery of
Paclitaxel After Stent Implantation for Prevention of Re-
stenosis in Comparison With Implantation of a Bare Metal
Stent Alone or With Implantation of a Paclitaxel-Coated
Stent) study used a different balloon design (Genie catheter,
Acrostak, Geneva, Switzerland) with distal and proximal
occlusive segments and a central segment that allowed for local
delivery of fluid paclitaxel to the vessel wall (16) (Table 3). The
theoretical advantages of such a design are the flexibility ofusing different drugs and the possibility of treating longer or
more complex vessel segments medically without mechan-
ical trauma. Compared with BMS-only patients, patients
randomized to receive a BMS plus local paclitaxel demon-
strated superior angiographic results and showed noninferiority
compared with paclitaxel-eluting stents. Correspondingly, re-
vascularization rates were identical in both the BMS plus local
paclitaxel and DES arms, but they were halved when com-
pared with revascularization rates in the BMS-only arm. The
encouraging results prompted the investigators to start a
registry evaluating the use of this device in in-stent restenosis,
chronic total occlusions (CTO), and bifurcation lesions.
The largest randomized trial to date involving DCB in coro-
nary applications is PEPCAD III, which investigated the
Coroflex DEBlue system (hybrid of BMS premounted onto
a SeQuent Please DCB) (B.
Braun Melsungen AG) as a pos-
sible alternative to DES, compar-
ing it to the Cypher sirolimus-
eluting stent (Cordis Corporation,
Miami Lakes, Florida) in patients
with a single de novo lesion (17).
In this first evaluation of a DCB
BMS hybrid, it failed to meet
noninferiority to DES, showing
almost 3 times higher in-stent
LLL, translating to significantly
more revascularizations. How-
ever, the result obtained by this
combination system was at least
comparable to published data on
paclitaxel-eluting stents, and in-
segment LLL analysis demon-
strated possible DCB efficacy at
the stent margins, which was
comparable to that achieved by
sirolimus-eluting stents. Al-
though there was no difference
in MACE rates (15% vs. 18%),
ST was higher in the Coroflex DEBlue group than in the
DES group (2.0% vs. 0.3% p  0.05), though duration of
DAPT was the same at 6 months.
The SeQuent Please DCB was also used in conjunction
with the endothelial progenitor cell (EPC)-capturing stent
(OrbusNeich Medical GmbH, Wiesbaden, Germany) in
the PERfECT Stent (Prospective, Randomized Trial Eval-
uating a Paclitaxel-Coated Balloon in Patients Treated
With EPC Stents for De Novo Coronary Artery Disease)
study (18). Theoretically, this combination reduced neoin-
timal proliferations and ST risks by facilitating rapid endo-
thelialization. Patients randomized to EPC stent implanta-
tion followed by DCB post-dilation demonstrated superior
Abbreviations
and Acronyms
BMS  bare-metal stent(s)
CTO  chronic total
occlusion(s)
DAPT  dual antiplatelet
therapy
DCB  drug-coated
balloon(s)
DES  drug-eluting stent(s)
EPC  endothelial progenitor
cell
LLL  late lumen loss
MACE  major adverse
cardiac event(s)
MB  main branch
PCI  percutaneous
coronary intervention
SB  side branch
ST  stent thrombosis
TLR  target lesion
revascularizationLLL and markedly reduced restenosis rates from 23.2% to
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alone. No ST events occurred in either group. The contrast-
ing efficacy and safety results in this trial as compared to
PEPCAD III may be related to different procedural tech-
niques. In PEPCAD III, the premounted BMS on DCB
may have affected negatively on paclitaxel dose, distribution,
and retention in the vessel wall, whereas the EPC stent and
DCB were 2 separate devices in the PERfECT Stent study.
Mandatory pre-dilation was performed in the PERfECT
Stent study, whereas direct stenting was performed in
one-half of the PEPCAD III patients. Furthermore, the use
of EPC stents and their purported effects on promoting
endothelialization may have eradicated ST risks even
though the duration of DAPT was halved.
Other DCB  BMS strategies have also been tested
against newer-generation DES with less compelling results.
Pre-dilation with the Elutax DCB (Aachen Resonance,
Table 1. Overview of DCB Used in Clinical Trials of De Novo Coronary Lesio
Drug-Coated Balloon Manufacturer
Dior I Eurocor (Bonn, Germany)
Dior II Eurocor (Bonn, Germany)
Elutax Aachen Resonance
(Aachen, Germany)
Genie Acrostak Corp. (Geneva, Switzerland)
In.Pact Falcon Medtronic-Invatec
(Frauenfeld, Switzerland)
Moxy Lutonix Inc. (Maple Grove, Minnesota)
Pantera Lux Biotronik (Bulach, Switzerland)
SeQuent Please B. Braun Melsungen AG
(Berlin, Germany)
Coroﬂex DEBlue (Hybrid system
of Coroﬂex blue cobalt
chromium BMS premounted
onto SeQuent Please DCB)
B. Braun Melsungen AG
(Berlin, Germany)
BMS bare-metal stent(s); DCB drug-coated balloon.
Table 2. Clinical Trials of DCB Use in Small Vessel Disease
Study Design Patients, N
PEPCAD I SeQuent Please 118
PICCOLETTO Dior I vs. Taxus 57
Spanish DIOR registry Dior I/II 103
BELLO In.Pact Falcon vs. Taxus 182
DCB-Only Small Vessel Disease
Worldwide registry
SeQuent Please Ongoing
BELLO Balloon Elution and Late Loss Optimization study; DIOR Results of Paclitaxel Eluting
Disease trial; PICCOLETTO Paclitaxel-Coated Balloon Versus Drug-Eluting Stent During Percuother abbreviations as in Table 1.Aachen, Germany) followed by BMS was significantly
inferior to the everolimus-eluting Xience DES (Abbott
Vascular, Abbott Park, Illinois) with excessive revascular-
ization rates at 9 months (19). Post-dilation with SeQuent
Please DCB following BMS was inferior to Xience in
inhibiting neointimal proliferation as assessed by optical
coherence tomography (20).
The differing efficacy of the DCB  BMS combination
from the preceding studies may in part be influenced by the
sequence of using DCB for either pre- or post-dilation in
conjunction with BMS. The following studies were de-
signed to examine this issue.
The INDICOR (Paclitaxel-Eluting PTCA-Balloon
Catheter in Combination with a Cobalt-Chromium Stent
to Treat Coronary Artery Disease in a Real World Scenario)
pilot trial randomized patients using the SeQuent Please
DCB  BMS (21); and the De Novo Pilot study used the
-Delivery Technology Excipient Dose Density, g/m2
orous balloon Dimethyl sulfate 3
orous balloon Shellac 3
d None 2
orous double balloon None
Uses a liquid drug
delivery catheter
10 mol/l
d FreePac urea 3
d Nonpolymeric 2
d Butyryl-tri-hexyl citrate 3
d Iopromide 3
d Iopromide 3
rimary Endpoint
llow-Up, Months)
TLR, %
(Follow-Up, Months)
Bailout Stent
Rate, % Ref. #
.18 mm in DCB-only,
3 in DCB  BMS (6)
4.9 in DCB-only, 27.1 in
DCB  BMS (12)
28 (12)
ter stenosis 43.6%
24.3% (6)
feriority not met
32.1 vs. 10.3 (9) 36 (13)
.34 mm (6) 3 (12) 7 (14)
.09 vs. 0.30 mm (6)
iority of DCB
4.4 vs. 7.7 (6) 21 (15)
registry; LLL late luminal loss; PEPCAD Paclitaxel Eluting PTCA Balloon in Coronary Artery
s Coronary Intervention of Small Coronary Vessels study; TLR target lesion revascularization;ns
Drug
Nanop
Nanop
Coate
Nanop
Coate
Coate
Coate
Coate
CoateP
(Fo
LLL 0
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vs.
Nonin
LLL 0
LLL 0
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1005Moxy DCB (Lutonix, Maple Grove, Minnesota) plus BMS
(22). Either sequence, DCB first or BMS first, was found to
result in similar LLL, MACE, and in-stent neointimal
hyperplasia assessed by optical coherence tomography. The
In.Pact Falcon DCB (Medtronic-Invatec) is currently being
tested for pre- versus post-dilation against BMS as the
control (the IN-PACT CORO [Intimal Hyperplasia Eval-
uated by Optical Coherence Tomography (OCT) in De
Novo Coronary Lesions Treated by Drug-Eluting Balloon
and Bare-Metal Stent] trial, NCT01057563). These studies
suggest that as long as a BMS is not premounted onto a
DCB, either sequence of DCB use for pre- or post-dilation
results in similar efficacy comparable to that of paclitaxel-
eluting stents. The clinical significance is that BMS may be
used as a bailout strategy for a suboptimal DCB angioplasty
Table 3. Clinical Trials of DCB Used in Combination With BMS
Study Design Patients, N
LOCAL TAX Genie  BMS vs.
BMS vs. Taxus
202
PEPCAD III Coroﬂex DEBlue vs. Cypher 637
PERfECT SeQuent Please 
EPC-capturing stent vs.
EPC-capturing stent
120
Liistro et al. Elutax  BMS vs. Xience 125
OCTOPUS BMS  SeQuent Please
vs. Xience
80
INDICOR SeQuent Please followed by BMS
vs. BMS followed by SeQuent
Please
97
De Novo Pilot study Moxy followed by BMS vs.
BMS followed by Moxy
26
IN-PACT CORO In.Pact Falcon for pre- or post-
dilation followed by BMS
PEPCAD IV SeQuent Please 
BMS vs. Taxus
84
PEPCAD CTO BMS followed by SeQuent Please
vs. Taxus
50
DEBAMI SeQuent Please  BMS 30
DEB-AMI Dior II  BMS vs.
BMS vs. Taxus
149
PAPPA Pantera Lux 100
CTO  chronic total occlusions; DEBAMI  Drug-Eluting Balloon in Acute Myocardial Infarction
endothelial progenitor cell; INDICORPaclitaxel-ElutingPTCA-BalloonCatheter inCombinationWit
Intimal Hyperplasia Evaluated by Optical Coherence Tomography (OCT) in De Novo Coronary Lesio
of Paclitaxel After Stent Implantation for Preventionof Restenosis inComparisonWith Implantationo
events; OCToptical coherence tomography;OCTOPUSOptical Coherence Tomography to Evalu
in Primary Percutaneous Coronary Intervention inAmsterdam study; PERfECTProspective, Random
Artery Disease; other abbreviations as in Tables 1 and 2.result.The motivation for combining BMS and DCB in de
novo lesions was to reduce the need for prolonged DAPT.
However, the results of this combination strategy showed
higher late loss, posed a higher ST risk when compared with
best-in-class DES, and did not have the proven ability to
reduce the DAPT duration. Therefore, the future of this
combination strategy is in question because of the inferiority
of DCB  BMS to DES, higher costs, and no apparent
dvantage.
CB  BMS in Diabetes Mellitus
Diabetic vessels are usually small in caliber, and coupled
with high plaque burden and diffuse nature of lesions, the
risk of restenosis is extremely high even with DES use
imary Endpoint
llow-Up, Months)
TLR, %
(Follow-Up, Months)
Bailout Stent
Rate, % Ref. #
61 vs. 0.99 vs.
4 mm (6)
13.4 vs. 22.1 vs. 13.4 (6) (16)
41 vs. 0.16 mm (9)
feriority not met
10.5 vs. 4.7 (17)
34 vs. 0.88 mm (6) 4.8 vs. 17.2 (6) (18)
feriority not met 14 vs. 2 (9) (19)
eointimal
liferation 15.69 vs.
21 mm3/cm (6)
fference in stent
ut coverage
4 vs. 2 (6) (20)
50 vs. 0.49 mm (6)
fference
4.1 vs. 2.1 (12) (21)
eointimal volume
struction 25.5% vs.
9% (6)
fference
15.4 vs. 15.4 (6) (22)
eointimal area and
ut coverage (6)
NCT01057563
51 vs. 0.53 mm (6)
fference
7.7 vs. 8.3 (9) (26)
64 vs. 0.43 mm (6)
fference
12.5 vs. 12.5 (6) (27)
7% (12) 17 (12) (31)
64 vs. 0.74 vs.
1 mm (6)
fference between
BMS and BMS
20 vs. 17.6 vs. 2 (6) (32)
3% (1) 2 (1) 41 (33)
B-AMI  Drug Eluting Balloon in Acute ST-Segment Elevation Myocardial Infarction trial; EPC 
alt-ChromiumStent to Treat CoronaryArteryDisease in a RealWorld Scenario trial; IN-PACTCORO
ed by Drug-Eluting Balloon and Bare-Metal Stent study; LOCAL TAX Local Intracoronary Delivery
-Metal StentAloneorWith Implantationof a Paclitaxel-CoatedStent;MACEmajor adverse cardiac
litaxel-ElutingBalloons and Everolimus ElutingCoronary Stents; PAPPAPaclitaxel-ElutingBalloon
rial Evaluating a Paclitaxel-Coated Balloon in Patients TreatedWith EPC Stents for DeNovoCoronaryPr
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1006neously along the entire device length and may offer a
valuable treatment alternative. PEPCAD IV randomized
patients to the SeQuent Please DCB  BMS versus Taxus
Liberté DES in diabetic patients (26). Results demonstrated
comparable angiographic and clinical outcomes despite the
DCB  BMS group undergoing less pre-dilation (31% vs.
97%) and achieving lower post-procedure minimum lumen
diameter. However, this result may not be sufficient to
demonstrate any added advantage of DCB  BMS when
ompared with the limus-family of DES in treating diabetic
atients.
CB  BMS in CTO
The theoretical advantage of homogeneous nonpolymeric
paclitaxel delivery over polymer-based DES was tested in a
cohort of patients with native CTO (27). In the PEPCAD-
CTO trial, following successful balloon dilation, the entire
lesion length was covered with BMS followed by SeQuent
Please DCB treatment in the stented segments and beyond
the edges. The BMS  DCB group achieved similar
ngiographic and clinical restenosis rates as compared to
istorically matched controls of CTO patients treated with
paclitaxel-eluting stent. This trial offers a new and
xpanding possibility of DCB use in increasingly complex
esion subsets.
CB  BMS in Acute Myocardial Infarction
DES use in acute myocardial infarction reduces restenosis,
but it carries the risks of uncovered stent struts and late
malapposition, which could potentially increase the risk of
late ST, especially with premature cessation of DAPT
(28–30). DCB technology in this highly inflammatory setting
provides the opportunity for highly concentrated, rapid local
drug release and the avoidance of sustained drug-polymer
effects on the vessel wall. If the culprit lesion is only briefly
exposed to the antiproliferative drug, theoretically endothelial
healing and function should not be affected. However, the
recent clinical data have been disappointing.
In the DEB-AMI (Drug-Eluting Balloon in Acute
Myocardial Infarction) pilot trial, despite adequate lesion
preparation with thrombectomy and pre-dilation followed
by SeQuent Please DCB  BMS, restenosis was unaccept-
ably high, leading to a target vessel revascularization rate of
17% at 1 year (31). Angiography at 9 months demonstrated
in-stent LLL of 0.48 mm. It may be of concern that 2 cases
(6%) of ST occurred, 1 while still on DAPT at 2 months
and another at 6 months on single-agent therapy.
Perhaps the clearest signal that the DCB  BMS
approach has no role in acute myocardial infarction comes
from the recently published DEB-AMI trial (32). In pri-
mary PCI, the Dior-II DCB  BMS combination con-
ferred no advantage over BMS alone, with similar 6-monthLLL, binary restenosis, and MACE on follow-up. In
contrast, those receiving DES showed significantly superior
angiographic and clinical outcomes. Optical coherence to-
mography subanalysis on DCB  BMS patients demon-
strated significantly more uncovered and malapposed struts
compared with BMS patients, but less compared with DES
patients, suggesting that although no apparent angiographic
and clinical benefit on restenosis was demonstrated, there is
a drug effect induced by the DCB on the vessel wall. These
disappointing results were attributed to insufficient pacli-
taxel bioavailability at the treatment site, less pre-dilation
(60% in DCB  BMS, 100% in others), and absence of
DCB treatment in segments receiving additional BMS
implantation (up to 20% of patients in the DCB subgroup).
Much is still unknown, however, about drug uptake in
ruptured plaques with high thrombus burden, which war-
rants further pharmacokinetic studies. Perhaps the efficacy
of a DCB is hampered by the presence of a BMS, and the
same investigators are enrolling patients for a DCB-only
strategy. This approach, however, is limited by a depen-
dence on bailout stenting, as demonstrated in the PAPP-A
(Paclitaxel-Eluting Balloon in Primary Percutaneous Cor-
onary Intervention in Amsterdam) pilot study that recorded
a bailout rate of 41% (33), which may limit long-term
efficacy.
DCB-Only Approach in De Novo Coronary Lesions
The emerging evidence thus far suggests that a DCB-only
strategy achieves superior LLL than does DCB  BMS,
ith a bailout rate of up to 25% (Table 4). Increased late loss
n the DCB  BMS group could be reasoned by inflam-
mation induced by deeper penetration of stent struts into
the vessel wall and the antiproliferative drug transfer from
DCB, which lacks sufficient depth.
To evaluate this DCB-only strategy, the Valentines II
registry (Table 5) was set up using DCB as an adjunct to
balloon angioplasty in treating de novo coronary stenoses
(34). In a cohort of 103 patients, the primary endpoint of
MACE at 8 months was 8.7%; target vessel revasculariza-
tion was 6.9%, demonstrating efficacy; and cardiac death
and myocardial infarction were 2%, demonstrating safety.
The results were even more impressive in the nondiabetic
subgroup as compared to the diabetics (MACE 6.8% vs.
13.8%, respectively). This trial achieved high pre-dilation
rates at 85%; bailout stenting occurred in 11.3%. A snapshot
angiographic follow-up demonstrated LLL of 0.30 mm and
a 10.7% binary restenosis rate. The results of this study were
similar to the Spanish DIOR Registry for small vessels. A
similar all-comer SeQuent Please WorldWide Registry
demonstrated a much higher rate of bailout stenting (35).
Patients with an additional BMS, however, had similarly
low rates of TLR and MACE at 10 months when compared
with patients receiving a DCB only. These trials offer
h; SB
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1007DCB-only as a viable alternative to stenting in patients who
may be unsuitable for DES implantation.
DCB-Only Approach In Diffuse Disease
Stent length independently predicts restenosis and stent
thrombosis (36,37). The attractiveness of a DCB-only
approach with spot-stenting is that it reduces the amount of
metal in the vessels while retaining the possibility of future
coronary artery bypass grafting. The Pilot Long Lesion
Study enrolled 12 patients (mean lesion length of 74 mm)
and employed optimal balloon angioplasty followed by
DCB, and if required, spot-stenting with BMS for flow-
limiting dissections and/or significant residual stenoses (38).
Intravascular ultrasound was used to guide and optimize
PCI results. Six-month follow-up demonstrated LLL of
0.48 mm, with 16% binary restenosis leading to TLR. With
encouraging results from this preliminary analysis, the
STARDUST (Spot Bare-Metal Stenting Provisional Im-
plantation plus Drug-Eluting Balloon Against Drug-
Table 4. Comparison of DCB-Only vs. DCB  BMS An
Study DCB Used D
PEPCAD I SeQuent Please 0.18
Spanish DIOR
registry
Dior I 0.34 (
BELLO In.Pact Falcon 0.03
LOCAL TAX Genie
PEPCAD III SeQuent Please 0.12 (
PERfECT SeQuent Please
INDICOR SeQuent Please
De Novo Pilot study Moxy
PEPCAD IV SeQuent Please 0.37 (
PEPCAD CTO SeQuent Please
DEBAMI SeQuent Please 0.42 (
DEB-AMI Dior II
Valentines II Dior II 0.30 (
Pilot Long Lesion study Unknown 0.48 (
DEBIUT trial Dior I 0.11 (
PEPCAD V SeQuent Please 0.12 (
DEBIUT Drug Eluting Balloon in Bifurcations Trial; MBmain branc
Table 5. Clinical Trials Using a DCB-Only Strategy
Study Design Patients, N
Valentines II Dior II 103 M
SeQuent Please Worldwide
registry
SeQuent Please 572 M
Pilot Long Lesion study DCB  BMS spot stent 12 L
STARDUST DCB  BMS spot stent vs. DES OngoingDES drug-eluting stent(s); STARDUST Spot Bare-Metal Stenting Provisional Implantation Plus Drug-EluEluting Stenting) trial is currently being conducted to test
this approach against DES.
DCB in Bifurcation Lesions
Tackling the side branch (SB) remains a significant chal-
lenge in coronary bifurcation PCI. Even with DES use, SB
treatment often results in unacceptably high restenosis rates.
Based on recent trial results, the approach of main branch
(MB) stenting with provisional SB stenting has become the
preferred method (39,40). In this regard, DCB treatment of
the SB may prove advantageous as compared to regular
balloon angioplasty. With these hypotheses, several studies
have evaluated DCB in bifurcation lesions (Table 6).
The DEBIUT (Drug Eluting Balloon in Bifurcation
Utrecht) registry used the Dior-I DCB to treat both the
MB and SB following adequate pre-dilation with regular
balloons (41). This was followed by the provisional
T-stenting technique with BMS in the MB and final kissing
post-dilation with normal balloons. No patients required
aphic LLL and Bailout Stenting Rates
LLL, mm
ly DCB  BMS Bailout Stenting, %
0.73 28
l) 7
0.33 21
0.61
ment) 0.41 (In-stent)
0.34
0.5
0.49
ment) 0.51 (In-stent)
0.64
ment) 0.48 (In-stent)
0.64
l) 11
l)
0.42 (MB) 7.5 (SB stenting)
0.66 (SB) 14 (SB stenting)
side branch; other abbreviations as in Tables 1 to 3.
rimary Endpoint
llow-Up, Months)
TLR, %
(Follow-Up, Months)
Bailout Stent
Rate, % Ref. #
.7% (8) 2.9 (8) 11.9 (34)
.6% in DCB-only,
in DCB  BMS (10)
1% in DCB-only,
2.4% in DCB  BMS (10)
29 (35)
mm (6) 16 (6) (38)giogr
CB On
overal
In-seg
In-seg
In-seg
overal
overal
SB)
SB)P
(Fo
ACE 8
ACE 2
2.4%
LL 0.48ting Balloon Against Drug-Eluting Stenting; other abbreviations as in Tables 1 to 3.
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1008additional BMS in SB treatment. There was no MACE
reported at the 4-month clinical follow-up.
Using this provisional T-stenting technique, the DEBIUT
(Drug Eluting Balloon in Bifurcations Trial), which random-
ized patients in 3 arms: Dior-I DCB pre-treatment 
BMS; BMS with uncoated balloon; and paclitaxel DES
with uncoated balloon (42). Despite achieving good results
with DCB  BMS (MB LLL: 0.41 mm; SB LLL: 0.19
mm), it failed to demonstrate superiority over BMS mostly
due to unexpectedly good results in the normal balloon
angioplasty-treated SB of both BMS and DES arms, and it
may also be related to the inferior drug delivery attributes of
the Dior-I DCB.
The single-arm PEPCAD V trial evaluated pre-treatment
of both SB and MB using the SeQuent Please DCB followed
by provisional T-stenting of the MB with BMS similar to
DEBIUT, except there was no obligatory pre-dilation of SB
using a normal balloon (43). The procedure was successful
in all patients, meeting the study’s primary endpoint. SB
stenting occurred in 14.3% of patients. Angiographic
follow-up at 9 months demonstrated comparable results to
historical control subjects with BMS-only in the MB and a
DES-like effect in the SB. Consistent with prior observa-
tions, DCB-only SB treatment results in superior LLL as
compared to DCB BMS (0.12 vs. 0.66 mm, respectively).
MACE occurred in 10.7% of patients, and 2 patients (7.1%)
had late ST beyond the prescribed 3 months of DAPT that
was attributed to incomplete stent apposition.
Separately, another group of investigators evaluated bi-
furcation treatment with 4 different new-generation DCB
(SeQuent Please, In.Pact Falcon, Dior-II, and Pantera Lux
Table 6. Clinical Trials of DCB Use in Bifurcation Lesions
Study Design Patients, N
Pri
(Fol
DEBIUT registry Dior I (MB  SB) followed
by BMS MB
20 MACE
DEBIUT trial Dior I (MB  SB) followed
by BMS MB vs. BMS MB
vs. DES MB
117 LLL d
0.4
LLL S
0
Super
ov
PEPCAD V SeQuent Please (MB  SB)
followed by BMS MB
28 LLL M
LLL S
Sgueglia et al. BMS MB followed by
kissing DCB (SeQuent
Please, In.Pact Falcon,
Dior II, Pantera Lux)
12 Proce
10
No M
KISSING DEBBIE BMS MB followed by
kissing DCB
Ongoing
BABILON SeQuent Please SB 
Taxus MB vs. Taxus MB
Ongoing
BABILON  Study of the Paclitaxel-Coated Balloon Catheter in Bifurcated Coronary Lesions; KISSIN
abbreviations as in Tables 1 to 5.[Biotronick, Bulach, Switzerland]) (44). The rationale inthis study was to avert primary SB pre-dilation, which may
increase the risk of dissection and SB stenting. Instead,
provisional bare-metal stenting with final kissing balloon
using DCB was employed with 100% procedural success; no
MACE was reported at a mean follow-up of 8 months. A
prospective registry of the kissing DCB technique is ongo-
ing (KISSING DEBBIE [Efficacy Study of Kissing Drug-
Eluting Balloons in Coronary Bifurcation Lesions] study,
NCT01009996).
The preceding trials used BMS in the MB, as there was no
significant safety data for DES  DCB. The BABILON
(Study of the Paclitaxel-Coated Balloon Catheter in Bifurcated
Coronary Lesions [NCT01278186]) is currently being con-
ducted evaluating the SeQuent Please DCB in SB treatment
with paclitaxel DES in the MB. The possibility of using a
DCB alone in bifurcations should also be considered in future
studies. More data are needed comparing DCB strategies in
bifurcation treatment against the use of newer-generation
DES, which have improved safety and efficacy. As of now,
DCB treatment of the SB appears promising in a provisional
SB stenting approach.
DCB  DES
Patients with high-risk lesions for restenosis, such as
insulin-dependent diabetes and very diffuse lesions, may
benefit from added doses of antiproliferative agents in the
vessel wall. At present, though, there are no clinical or
pre-clinical data on the efficacy and safety of DCB  DES.
ndpoint
, Months)
TLR, %
(Follow-Up, Months)
Bailout Stent
Rate, % Ref. #
(4) 0 (4) (41)
B 0.41 vs.
.19 mm
vs. 0.21 vs.
m (6)
of DCB
not met
20 vs. 27 vs. 15 (18) 7.5 (SB stenting) (42)
mm
mm (9)
3.8 (9) 14 (43)
uccess
)
0 (8) (44)
NCT01009996
NCT01278186
BIE  Efficacy Study of Kissing Drug-Eluting Balloons in Coronary Bifurcation Lesions study; othermary E
low-Up
none
istal M
9 vs. 0
B 0.19
.11 m
iority
er BMS
B 0.38
B 0.21
dural s
0%
ACE (8
G DEBThe closest available evidence comes from studies evaluating
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1009overlapping DES. Initial safety concerns arose from the
animal studies, where overlapped segments using homoge-
neous DES have higher drug and polymer concentrations,
resulting in delayed healing and increased inflammation
(45). Moreover, overlapping heterogeneous paclitaxel and
sirolimus DES had better histological outcomes compared
with homogeneous drug use (46). However, clinical data
suggested no difference between overlapping homogeneous
and heterogeneous DES use (47,48). Overlapped DES
result in higher restenosis rates and adverse clinical out-
comes compared with nonoverlapped DES (49). Herein lies
the attractiveness of using a single layer of DES (with added
antiproliferative effects) over DCB and should be the focus
of future studies.
DAPT Requirements With DCB
Using a protocol of 1-month DAPT, earlier trials demon-
strated no thrombotic complications even beyond 2 years
(6,7). Whereas a DCB-only approach confers little risk of
vessel thrombosis, this risk increases when coupled with a
BMS. Most studies prescribed 3 months of DAPT follow-
ing clopidogrel-loading with reasonable safety; however,
there were still reports of thrombosis occurring beyond 6
months (Table 7). Perhaps the DCB  BMS combination
Table 7. Vessel Thrombosis Rate in DCB Use and Duration of DAPT
Study Device
PEPCAD I SeQuent Please 0 (0/82) i
6.3 (2/32)
PICCOLETTO Dior I 0 (0/18) i
0 (0/10) i
Spanish DIOR registry Dior I/II 1 (1/103)
BELLO In.Pact Falcon 0 (0/94)
LOCAL TAX Genie  BMS 0 (0/67)
PEPCAD III Coroﬂex DEBlue 2 (6/310)
PERfECT SeQuent Please  EPC-capturing stent 0 (0/62)
INDICOR SeQuent Please  BMS 6.1 (3/49)
3.1 (1/48)
De Novo Pilot study Moxy  BMS 0 (0/26)
PEPCAD IV SeQuent Please  BMS 0 (0/45)
PEPCAD CTO SeQuent Please  BMS 0 (0/48)
DEBAMI SeQuent Please  BMS 6.7 (2/30)
(1 patien
DEB-AMI Dior II  BMS 4 (2/50) (
Valentines II Dior II 0 (0/103)
Pilot Long Lesion study DCB ( provisional BMS) 0 (0/12)
DEBIUT registry Dior I  BMS 0 (0/20)
DEBIUT trial Dior I  BMS 0 (0/40)
PEPCAD V SeQuent Please  BMS 7 (2/28)
(1 patien
Sgueglia et al. 4 different DCB  BMS 0 (0/12)DAPT dual antiplatelet therapy; other abbreviations as in Tables 1, 2, 3, 5, and 6.should be treated like DES implantation with 6 to 12
months of DAPT. This is even more relevant in lesion
subsets at high thrombotic risk, such as bifurcations; here,
DAPT should be considered for a full 12 months. The
hypothesis of reducing DAPT duration with various DCB
treatments is not supported by current data. Future recom-
mendations will depend on more clinical evidence, particu-
larly if the DCB technique can be optimized to avoid
stenting.
Conclusions and Future Perspectives
The limitations of the currently available evidence are that
the studies are mainly based on small registries and few
small randomized trials. Moreover, the results offered by
these studies do not comprehensively answer specifically to
the DCB indications. Most of these studies use LLL as a
surrogate endpoint to restenosis instead of clinical out-
comes. Longer-term follow-up data are also desired; how-
ever, these emerging data hold promise mainly in lesion
subsets in which implanting a stent is not desirable or is
technically challenging.
For now, a DCB-only approach appears feasible in
small-vessel coronary artery disease. Similarly, DCB use
el Thrombosis Rate,
% (n/N)
Duration of DAPT,
Month(s)
Clinical Follow Up,
Months
only
B  BMS
1
3
6
only
 BMS
1
3
9
Not available 12
Not available 6
6 6
6 9
3 6
B 1st
S 1st
3 12
3 6
3 6
3 6
months, 1 patient at 6 months)
3 12
nt at day 4, 1 patient at day 5) Not available 6
3 7.5
Not available 6
3 4
3 12
months, 1 patient at 8 months)
3 9
3 8Vess
n DCB
in DC
n DCB
n DCB
in DC
in BM
t at 2
1 patie
t at 6
b
c
B
t
t
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1010shows promise in SB treatment in bifurcation lesions,
although the technical aspects of this complex procedure are
still being evaluated. More data are needed, especially in
novel indications such as CTO, diabetes, and diffuse
disease. The all-comer registries show DCB to be safe
and effective in routine clinical use, with acceptable
crossover rates to bailout stenting. Future trials evaluat-
ing the DCB-only strategy with bailout or spot-stenting
may be required to demonstrate noninferiority to newer-
generation DES.
Not all DCB are created equal. Although most of the
currently available DCB for coronary applications are based
on similar principles using similar paclitaxel doses, specific
elution kinetics may differ because of the coating and may
result in differing tissue retention characteristics. Unless we
have randomized trials with head-to-head data on the
different DCB, it is difficult to assume a “class effect.”
Moreover, these drug-elution profiles have not yet been
defined in certain pathologies, such as acute myocardial
infarction with high thrombus burden.
Development of paclitaxel DCB originated when the
Taxus stent was successfully tested and expectations were
high. Moreover, coating methods have evolved such that
manufacturers are now familiar with the principles of using
paclitaxel. However, we now know that Taxus is inferior to
the limus-based drugs in treating restenosis and ST (50,51).
These are serious issues to perhaps redirect the industry’s
focus in designing the next generation of DCB with
limus-based drugs. The challenge is in developing more
advanced carrier technology (possibly with polymeric nano-
particles) for the limus-based drugs to achieve more stable
tissue drug levels for optimal biologic effect (52–54). At
present, zotarolimus appears to have the best profile with
encouraging pre-clinical data (55).
Operator experience and technical expertise in DCB use
are paramount in obtaining good results. Ideally, the steno-
sis should first be adequately dilated with normal balloon
angioplasty to achieve a “stentlike” angiographic result,
followed by DCB use for drug delivery at nominal pressure
inflation. The DCB should be sized longer than the
angioplasty balloon to avoid geographic miss to prevent
restenosis in the untreated areas. Pre-dilation is thought to
create important “microdissections,” which facilitate drug
transfer through the intima and media. Based on current
evidence, a DCB-only strategy is preferred. However, in
cases of significant dissections, residual stenoses or acute
closure post-balloon angioplasty, treatment options include
DES-only and DCB  BMS. Particular attention should
e paid to avoid a geographic miss when a DCB is used in
ombination with a stent. Bailout stenting outcomes with
MS are inferior to a DCB-only strategy, and this limita-
ion must be considered when using a DCB especially in SB
reatment of bifurcation lesions.The DCB is still trying to find its role in coronary artery
disease treatment. Current evidence suggests DCB efficacy
and safety in coronary de novo lesions but does not support
superiority or even equivalence to the best-in-class DES.
We therefore believe that DCB should not be disruptive to
DES; when used carefully and with the right technique,
DCB may have a niche role in the treatment of coronary
lesions not suitable or ideal for DES implantation. Larger
randomized clinical trials, and perhaps a push for develop-
ing limus-based DCB, are required to further elucidate the
role of this technology.
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